Bayer/PPD Implitapide Development Follows Zetia Model As Statin Add-On
Executive Summary
PPD will adopt Merck/Schering-Plough's Zetia model in developing Bayer's implitapide as an add-on therapy in the lipid-lowering market, PPD subsidiary MRL International CEO Evan Stein, MD/PhD, said